Compare Stocks: ASRT, AQST, CRMD, and PHAT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.76 +3.0%	$4.67	$2.93 ▼ $7.55	$579.87M	1.49	2.24 million shs	2.32 million shs
ASRT Assertio	$23.50	$23.42	$8.61 ▼ $23.50	$151.81M	0.52	271,083 shs	N/A
CRMD CorMedix	$7.32 +0.5%	$7.86	$6.13 ▼ $13.02	$567.43M	1.4	869,869 shs	1.02 million shs
PHAT Phathom Pharmaceuticals	$7.13 +4.7%	$8.34	$6.52 ▼ $18.31	$550.93M	0.5	1.41 million shs	1.33 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+3.03%	+7.21%	-8.64%	+15.53%	-23.23%
ASRT Assertio	0.00%	0.00%	0.00%	0.00%	+76.43%
CRMD CorMedix	+0.55%	-1.35%	-10.51%	-12.86%	-35.05%
PHAT Phathom Pharmaceuticals	+4.70%	+0.71%	-24.39%	-43.46%	-35.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.76 +3.0%	$4.67	$2.93 ▼ $7.55	$579.87M	1.49	2.24 million shs	2.32 million shs
ASRT Assertio	$23.50	$23.42	$8.61 ▼ $23.50	$151.81M	0.52	271,083 shs	N/A
CRMD CorMedix	$7.32 +0.5%	$7.86	$6.13 ▼ $13.02	$567.43M	1.4	869,869 shs	1.02 million shs
PHAT Phathom Pharmaceuticals	$7.13 +4.7%	$8.34	$6.52 ▼ $18.31	$550.93M	0.5	1.41 million shs	1.33 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+3.03%	+7.21%	-8.64%	+15.53%	-23.23%
ASRT Assertio	0.00%	0.00%	0.00%	0.00%	+76.43%
CRMD CorMedix	+0.55%	-1.35%	-10.51%	-12.86%	-35.05%
PHAT Phathom Pharmaceuticals	+4.70%	+0.71%	-24.39%	-43.46%	-35.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	2.83	Moderate Buy	$8.60	80.67% Upside
ASRT Assertio	1.80	Reduce	$22.65	-3.62% Downside
CRMD CorMedix	2.78	Moderate Buy	$15.00	104.92% Upside
PHAT Phathom Pharmaceuticals	2.78	Moderate Buy	$21.25	198.04% Upside

Current Analyst Ratings Breakdown

Latest ASRT, AQST, CRMD, and PHAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	CRMD CorMedix	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$15.00
9/10/2026	AQST Aquestive Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$11.00
9/9/2026	PHAT Phathom Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$10.00
9/9/2026	PHAT Phathom Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$10.00
8/24/2026	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/14/2026	PHAT Phathom Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$18.00 ➝ $14.00
8/14/2026	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$13.00 ➝ $14.00
8/11/2026	CRMD CorMedix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
7/31/2026	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
7/31/2026	PHAT Phathom Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$25.00 ➝ $22.00
7/31/2026	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$54.09M	11.05	N/A	N/A	($0.28) per share	-17.00
ASRT Assertio	$118.71M	1.28	$0.02 per share	1,437.29	$14.63 per share	1.61
CRMD CorMedix	$311.71M	1.83	$2.06 per share	3.56	$5.14 per share	1.42
PHAT Phathom Pharmaceuticals	$175.11M	3.29	N/A	N/A	($6.14) per share	-1.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$83.78M	-$0.65	N/A	N/A	N/A	-144.63%	N/A	-52.40%	11/4/2026 (Estimated)
ASRT Assertio	-$30.38M	-$5.69	N/A	21.17	N/A	-34.94%	-38.72%	-13.32%	N/A
CRMD CorMedix	$163.05M	$2.14	3.42	52.29	1.35	40.49%	40.52%	20.61%	11/11/2026 (Estimated)
PHAT Phathom Pharmaceuticals	-$221.25M	-$1.28	N/A	6.15	N/A	-41.34%	N/A	-20.81%	10/29/2026 (Estimated)

Latest ASRT, AQST, CRMD, and PHAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	AQST Aquestive Therapeutics	-$0.10	N/A	N/A	N/A	$11.02 million	N/A
10/29/2026	Q3 2026	PHAT Phathom Pharmaceuticals	$0.07	N/A	N/A	N/A	$85.51 million	N/A
8/13/2026	Q2 2026	CRMD CorMedix	$0.2380	$0.29	+$0.0520	$0.29	$96.04 million	$101.93 million
8/11/2026	Q2 2026	AQST Aquestive Therapeutics	-$0.1050	-$0.18	-$0.0750	-$0.18	$11.42 million	$13.82 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	7.19	6.74
ASRT Assertio	0.52	1.82	1.57
CRMD CorMedix	0.31	2.56	2.36
PHAT Phathom Pharmaceuticals	N/A	1.92	1.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
ASRT Assertio	48.96%
CRMD CorMedix	34.18%
PHAT Phathom Pharmaceuticals	99.01%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	6.81%
ASRT Assertio	5.70%
CRMD CorMedix	3.50%
PHAT Phathom Pharmaceuticals	9.33%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	147	125.51 million	116.97 million	Optionable
ASRT Assertio	20	6.46 million	6.09 million	Optionable
CRMD CorMedix	191	77.94 million	75.22 million	Optionable
PHAT Phathom Pharmaceuticals	371	80.90 million	73.35 million	Optionable

ASRT, AQST, CRMD, and PHAT Headlines

Recent News About These Companies

Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting

October 8 at 8:00 AM | globenewswire.com

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Phathom Pharmaceuticals (NASDAQ:PHAT) Head-To-Head Analysis

October 7 at 3:59 AM | americanbankingnews.com

Phathom Pharmaceuticals stock draws a Moderate Buy consensus

October 6 at 11:52 PM | ad-hoc-news.deA

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of "Moderate Buy" from Analysts

October 6 at 4:15 AM | americanbankingnews.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock Rated "Moderate Buy" by Wall Street Brokerages

October 6 at 4:13 AM | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Sets New 1-Year Low - Here's Why

October 2, 2026 | marketbeat.com

Bank of America Corp DE Makes New Investment in Phathom Pharmaceuticals, Inc. $PHAT

October 2, 2026 | marketbeat.com

Reviewing Traws Pharma (NASDAQ:TRAW) & Phathom Pharmaceuticals (NASDAQ:PHAT)

October 1, 2026 | americanbankingnews.com

Phathom Pharmaceuticals Starts Registrational Phase 3 Voquezna Study

September 30, 2026 | finance.yahoo.com

Phathom Pharmaceuticals, Inc. Initiates Registrational Phase 3 Study Of VOQUEZNA For As-Needed Treatment Of Non-Erosive GERD

September 29, 2026 | marketscreener.comM

Phathom Pharmaceuticals avvia la fase 3 per VOQUEZNA nella NERD

September 29, 2026 | it.investing.com

Phathom Pharmaceuticals Initiates Phase 3 Study of VOQUEZNA for As-Needed Treatment of Non-Erosive GERD

September 29, 2026 | quiverquant.comQ

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

September 29, 2026 | globenewswire.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month Low - What's Next?

September 23, 2026 | marketbeat.com

Squarepoint Ops LLC Lowers Stock Position in Phathom Pharmaceuticals, Inc. $PHAT

September 23, 2026 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month Low - Time to Sell?

September 17, 2026 | marketbeat.com

PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law

September 16, 2026 | businesswire.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Sets New 1-Year Low - What's Next?

September 11, 2026 | marketbeat.com

Opaleye Management Inc. Purchases New Shares in Phathom Pharmaceuticals, Inc. $PHAT

September 11, 2026 | marketbeat.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Rating of "Moderate Buy" by Brokerages

September 11, 2026 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Rating Upgraded by Leerink Partners

September 10, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT, AQST, CRMD, and PHAT Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$4.76 +0.14 (+3.03%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$4.76 0.00 (-0.11%)

As of 10/8/2026 07:50 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Assertio NASDAQ:ASRT

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

CorMedix NASDAQ:CRMD

$7.32 +0.04 (+0.55%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$7.30 -0.02 (-0.25%)

As of 10/8/2026 07:50 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Phathom Pharmaceuticals NASDAQ:PHAT

$7.13 +0.32 (+4.70%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$7.13 0.00 (0.00%)

As of 10/8/2026 07:30 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASRT, AQST, CRMD, and PHAT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASRT, AQST, CRMD, and PHAT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASRT, AQST, CRMD, and PHAT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT, AQST, CRMD, and PHAT Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

Assertio NASDAQ:ASRT

CorMedix NASDAQ:CRMD

Phathom Pharmaceuticals NASDAQ:PHAT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASRT, AQST, CRMD, and PHAT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASRT, AQST, CRMD, and PHAT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASRT, AQST, CRMD, and PHAT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASRT, AQST, CRMD, and PHAT Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

Assertio NASDAQ:ASRT

CorMedix NASDAQ:CRMD

Phathom Pharmaceuticals NASDAQ:PHAT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools